A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Study Identifier
M10-752
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Schizophrenia
  • Study Drug
  • ABT-288
  • Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 60 Years

    Protocol Summary

    Evaluate the safety, tolerability and pharmacokinetics of ABT-288 in order to determine the maximum tolerated dose of ABT-288 in stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.

    Study Locations

    No locations found.